Structure-Activity Relationship Study of CYM51010, an agonist for the μ-δ Opioid Receptor Heterodimer

被引:0
|
作者
Watanabe, Ayaka [1 ]
Yamada, Shuma [1 ]
Yoshida, Haruka [1 ,2 ]
Inagaki, Miku [1 ,2 ]
Atsumi, Nao [1 ,2 ]
Matsushima, Aoba [1 ]
Takahashi, Naoki [1 ]
Ishibashi, Naoto [1 ,2 ]
Ogino, Takumi [1 ,2 ]
Someya, Ryoto [1 ,2 ]
Taguchi, Ai [1 ,2 ]
Kagaya, Ryo [1 ,2 ]
Ashizawa, Karin [1 ,2 ]
Mendori, Hinako [2 ,3 ]
Karasawa, Yusuke [2 ]
Ohshima, Kaori [2 ]
Yokoyama, Akinobu [3 ]
Nonaka, Miki [2 ]
Miyano, Kanako [2 ]
Karaki, Fumika [1 ,4 ]
Hirayama, Shigeto [1 ,4 ]
Itoh, Kennosuke [1 ,4 ]
Uezono, Yasuhito [2 ]
Fujii, Hideaki [1 ,4 ]
机构
[1] Kitasato Univ, Sch Pharm, Lab Med Chem, 5-9-1 Shirokanem,Minato Ku, Tokyo 1088641, Japan
[2] Jikei Univ, Sch Med, Dept Pain Control Res, 3-25-8,Nishi Shimbashi,Minato Ku, Tokyo 1058461, Japan
[3] Tokyo Univ Sci, Fac Pharmaceut Sci, Lab Mol Pathol & Metab Dis, Chiba 2788510, Japan
[4] Kitasato Univ, Sch Pharm, Med Res Labs, 5-9-1 Shirokane,Minato Ku, Tokyo 1088641, Japan
关键词
mu opioid receptor; delta opioid receptor; heterodimer; G protein-coupled receptor; analgesic; MORPHINE-TOLERANCE; LIGAND EFFICIENCY; SPLICE VARIANTS; DEPENDENCE; ANALGESIA; TARGET;
D O I
10.1248/cpb.c24-00188
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Although opioid analgesics are indispensable in treating pain, these drugs are accompanied by lifethreatening side effects. While clinically relevant opioid drugs target the mu opioid receptor (MOR), a heterodimer between the MOR and the delta opioid receptor (DOR) has emerged as another target to develop safer analgesics. Although some heterodimer-preferring agonists have been reported so far, it is still difficult to activate the MOR/DOR heterodimer selectively in the presence of MOR or DOR monomers/homodimers. To gain insights to develop selective agonists for MOR/DOR, herein we prepared analogs of CYM51010, one of the reported heterodimer-preferring agonists, and collected structure-activity relationship information. We found that the ethoxycarbonyl group was needed for the activity for the heterodimer, although this group could be substituted with functional groups with similar sizes, such as an ethoxycarbonyl group. As for the acetylaminophenyl group, not a type of substituent, but rather a substituent located at a specific position (para-position) was essential for the activity. Changing the linker length between the acetylaminophenyl group and the piperidine moiety also had deleterious effects on the activity. On the other hand, the substitution of the acetylamino group with a trifluoroacetylamino group and the substitution of the phenethyl group with a benzyl group diminished the activities for the monomers/homodimers while keeping the activity for MOR/DOR, which enhanced the selectivity. Our findings herein will play an important role in developing selective agonists for MOR/DOR and for elucidating the physiological roles of this heterodimer in analgesic processes and in the establishment of side effects.
引用
收藏
页码:711 / 730
页数:20
相关论文
共 50 条
  • [1] Structure-activity relationship study of nonpeptide δ-opioid receptor ligands
    Lahsen, J
    Schmidhammer, H
    Rode, BM
    HELVETICA CHIMICA ACTA, 2001, 84 (11) : 3299 - 3305
  • [2] The first structure-activity relationship study of oxytocin as a positive allosteric modulator for the ? opioid receptor
    Mizuguchi, Takaaki
    Miyano, Kanako
    Yamauchi, Risa
    Yoshida, Yuki
    Takahashi, Hideki
    Yamazaki, Ami
    Ono, Haruka
    Inagaki, Miku
    Nonaka, Miki
    Uezono, Yasuhito
    Fujii, Hideaki
    PEPTIDES, 2023, 159
  • [3] Structure-Activity Relationship of a Broad-Spectrum Insect Odorant Receptor Agonist
    Taylor, Robert W.
    Romaine, Ian M.
    Liu, Chao
    Murthi, Poornima
    Jones, Patrick L.
    Waterson, Alex G.
    Sulikowski, Gary A.
    Zwiebel, Laurence J.
    ACS CHEMICAL BIOLOGY, 2012, 7 (10) : 1647 - 1652
  • [4] Structure-activity relationship of bile alcohols as human farnesoid X receptor agonist
    Iguchi, Yusuke
    Kihira, Kenji
    Nishimaki-Mogami, Tomoko
    Une, Mizuho
    STEROIDS, 2010, 75 (01) : 95 - 100
  • [5] Structure-activity relationship of rubiscolins as δ opioid peptides
    Yang, SZ
    Sonoda, S
    Chen, LP
    Yoshikawa, M
    PEPTIDES, 2003, 24 (04) : 503 - 508
  • [6] The structure-activity relationship of Dmt-NH-X on opioid receptor affinity
    Fujita, Yoshio
    Motoyama, Takashi
    Li, Tingyou
    Miyazaki, Anna
    Yokoi, Toshio
    Tsuda, Yuko
    Ambo, Akihiro
    Sasaki, Yusuke
    Jinsinaa, Yunden
    Bryant, Sharon D.
    Lazarus, Lawrence H.
    Okada, Yoshio
    Peptides 2004, Proceedings: BRIDGES BETWEEN DISCIPLINES, 2005, : 842 - 843
  • [7] THE STRUCTURE-ACTIVITY RELATIONSHIP OF DMT-NH-X ON OPIOID RECEPTOR AFFINITY
    Fujita, Y.
    Motoyama, T.
    Li, T.
    Miyazaki, A.
    Yokoi, T.
    Tsuda, Y.
    Ambo, A.
    Sasaki, Y.
    Bryant, S. D.
    Lazarus, L. H.
    Okada, Y.
    JOURNAL OF PEPTIDE SCIENCE, 2004, 10 : 244 - 244
  • [8] Structure-Activity Relationship Study of Cannabidiol-Based Analogs as Negative Allosteric Modulators of the μ-Opioid Receptor
    Bosquez-Berger, Taryn
    Gudorf, Jessica A.
    Kuntz, Charles P.
    Desmond, Jacob A.
    Schlebach, Jonathan P.
    VanNieuwenhze, Michael S.
    Straiker, Alex
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (14) : 9466 - 9494
  • [9] BENZODIAZEPINES - RECEPTOR AND STRUCTURE-ACTIVITY RELATIONSHIP
    DASILVEIRA, MAB
    REVISTA BRASILEIRA DE MEDICINA, 1988, 45 (05) : 176 - 178
  • [10] Structure-activity relationship investigation of triazole-based kappa opioid receptor agonists
    Frankowski, Kevin J.
    Brust, Tarsis
    Lovell, Kimberly M.
    Yoo, Euna
    Bohn, Laura M.
    Aube, Jeffrey
    MEDICINAL CHEMISTRY RESEARCH, 2021, 30 (07) : 1386 - 1396